Replies to post #135901 on Biotech Values

[mcbio]

VSTM’s founder, Christoph Westphal, is the one who pressed the sale of Sirtis to GSK for $620M four years ago (#msg-28705020). VSTM has a current enterprise value of about $200M.

You think VSTM has a chance to follow in the former SIRT's footsteps as a potential buyout candidate down the road? Otherwise, are you bullish on VSTM's prospects?